Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As Michael mentioned earlier, in the fourth quarter, we strengthened our balance sheet, adding $258 million, providing strong validation of Syndax’s potential from both existing, as well as new high-quality institutional investors |
| 2023 was a year of tremendous progress in execution for Syndax, marked by the delivery of positive pivotal data and regulatory submissions for both revumenib and axatilimab |
| Both programs offer the potential for broad franchise opportunities beyond their initial registration indications, adding to Syndax’s long-term growth potential |
| Looking forward, our financial strength enables us to focus on the execution of advancing our pipeline and achieving an exceptional launch of revumenib and axatilimab later this year |
| We expect that our first-mover advantage and the experienced physicians will gain treating patients with revumenib could extend meaningfully beyond KMT2A and allow us to build a formidable franchise in the next few years, augmented by a second indication in NPM1 AML |
| These results reinforce its potential as a first- and best-in-class CSF-1R monoclonal antibody in chronic GVHD |
| We unanimously heard from KOLs at our ASH investor event and continue to hear from physicians today their belief that continued use of revumenib post-transplant should lead to the best possible outcomes and it is an attractive option for these patients |
| Newer entrants, Jakafi and Rezurock, have had successful commercial launches, which speaks to the unmet need in chronic GVHD and the substantial commercial opportunity for a differentiated agent such as axatilimab |
| Positive data from the pivotal AGAVE-201 trial presented at a plenary scientific session at ASH in December formed the basis of the BLA submission |
| Financially, we are in a very good position |
| I think, as we stated in our remarks, we think it’s a -- KMT2A is a really, I’d say, compelling opportunity commercially in the sense that we’ll have a first-to-market, best-in-class product to address patients even earlier than they are in a clinical trial |
| So I think this sets up as a really interesting new opportunity for a drug to come to market with really no competition at the current point -- at this current point to get in the way of a very successful launch |
| It’s quite clearly the superior dose in terms of efficacy, as well as tolerability |
| 2024 is shaping up to be a historical year for Syndax as we prepare to launch two first- and best-in-class products, and I am confident that we have the expertise, resources and determination to achieve our goals |
| Syndax is firmly on the path to distinguishing itself as a commercial-stage smid cap biotechnology company and with opportunities to expand well beyond the initial indications for revumenib and axatilimab, we envision creating long-term value with these franchises for years to come |
| Addressing inflammation and fibrosis in one mechanism of action is a key differentiator and also supports moving axatilimab earlier in the treatment paradigm to potentially prevent organ damage before it occurs |
| As evidenced by our positive pivotal trial readouts and two regulatory submissions for our two lead drug candidates, both of which are first and potentially best-in-class treatment, this is only the beginning of what’s to come for Syndax |
| So that’s an exciting development for the company, and obviously, we have great experience with the molecule and want to think that we’re involved |
| The data presentations have translated to continued strong enrollment in our clinical trials through additional engagement from the medical community, as well as additional requests for investigator-sponsored trials that could ultimately expand the use of the drug once approved |
| Physicians with whom we have engaged are impressed by revumenib’s ability to induce rapid tumor clearance in heavily pretreated patients, enabling many of them to undergo a potentially curative bone marrow transplant |
| markets and into other high-value indications could build significant additional value for axatilimab over the next few decades |
| As you have heard during the call, 2023 was a landmark year for growth and execution |
| Our first-mover advantage is of high strategic importance and we are busy ensuring that we successfully execute two first- and best-in-class drug launches |
| There are several reasons why we are excited to pursue fibrotic disease outside of chronic GVHD and why we have confidence that axatilimab may provide meaningful benefit in IPF |
| This triple combination was also well-tolerated at both active doses of revumenib in the trial, including the current monotherapy RP2D with no new or increased safety signals observed beyond what would be expected with venetoclax and a hypomethylating agent |
| We strengthened our balance sheet in the fourth quarter with an additional $258 million in cash, and Keith will go into more detail in our financials later in this call |
| Even more encouraging are the clinical data for axatilimab in patients with pulmonary manifestations of chronic GVHD, where clinically notable improvements in lung function have been observed |
| It’s worth noting that revumenib has been well tolerated in patients with relapsed or refractory NPM1 AML |
| I’m confident that we have the right plan and team in place to execute on them |
| Axatilimab was well-tolerated in the trial with a low 6% rate of discontinuation |
| Statement |
|---|
| What would ASTX727 do alone? And then second, on BAML, again, there’s some concerns about the combinability, particularly the dose of revumenib going forward in light of the SIP interaction that ven/aza |
| Right now, the only thing they have is steroids, and unfortunately, those do as much harm as they do good |
| So in terms of the ASH data, there are two controversial aspects that we keep debating with investors and curious to get your thoughts on those |
| In terms of BAML, I’m not sure that I understand why you think that there’s a challenge around dose selection both |
| As you can see, most patients experienced improvement or slowing of decline of pulmonary function, which is very unlikely to occur spontaneously |
| As a monotherapy agent, it’s obviously a very difficult disease state and we’re going to have some data in the second quarter of this year to first get at whether there’s sufficient activity there as a monotherapy agent and how the drug performs |
Please consider a small donation if you think this website provides you with relevant information